NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS stock has increased by 43.2% and is now trading at $16.37. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported $0.47 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to analysts' expectations of $21.07 million. Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. View Cellectis' earnings history.

7 brokerages have issued 12 month target prices for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $32.33 in the next twelve months. This suggests a possible upside of 97.5% from the stock's current price. View analysts' price targets for Cellectis.

News articles about CLLS stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cellectis earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutCellectis.

Cellectis saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 356,700 shares, an increase of 34.4% from the April 30th total of 265,400 shares. Based on an average daily volume of 147,800 shares, the short-interest ratio is currently 2.4 days. Currently, 0.8% of the company's shares are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Beam Therapeutics (BEAM), I-Mab (BDTX) and Regenxbio (RGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sarepta Therapeutics (SRPT) and Alibaba Group (BABA).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital International Investors (3.31%), Nikko Asset Management Americas Inc. (3.04%), Sumitomo Mitsui Trust Holdings Inc. (3.04%), Nikko Asset Management Americas Inc. (3.04%), Morgan Stanley (1.70%) and Morgan Stanley (1.70%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vident Investment Advisory LLC, Wells Fargo & Company MN, WS Management Lllp, Victory Capital Management Inc., and Victory Capital Management Inc..

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, ING Groep NV, JPMorgan Chase & Co., Ikarian Capital LLC, Advisor Group Holdings Inc., Trexquant Investment LP, Nikko Asset Management Americas Inc., and Nikko Asset Management Americas Inc..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $16.37.

Cellectis has a market capitalization of $695.23 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]